MASSPROT: supporting cancer research
pftplus |
Picture credit : Yvan Flamant
Thanks to the HDx-MS technology recently deloped within the MASSPROT platform (Woluwé site), a team of researchers from UCLouvain and the University of Lille has just reached an important milestone in cancer research by developing a revolutionary new compound: LIBX-A401.
This experimental treatment targets a key enzyme involved in the progression of certain tumors, paving the way for more effective and better-tolerated therapies.
The results of this research are published in Angewandte Chemie